{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:29:43Z","timestamp":1793910583946,"version":"4.8.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC APP2033152"],"award-info":[{"award-number":["NHMRC APP2033152"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.blre.2026.101435","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:47:33Z","timestamp":1790095653000},"page":"101435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia"],"prefix":"10.1016","author":[{"given":"Taylor A.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.C.","family":"Dymock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung K.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi S.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.blre.2026.101435_bb0005","article-title":"Children\u2019s Oncology Group blueprint for research: acute lymphoblastic leukemia","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0010","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (https:\/\/www.seer.cancer.gov) SEER*Stat Database: Incidence \u2013 SEER Research Data, 8 Registries, Nov 2025 Sub (1975\u20132023). National Cancer Institute; 2026. DCCPS, Surveillance Research Program; released April 2026, based on the November 2025 submission."},{"key":"10.1016\/j.blre.2026.101435_bb0015","unstructured":"Surveillance Research Program, National Cancer Institute SEER*Stat software. (seer.cancer.gov\/seerstat) version 9.0.42.2, https:\/\/seer.cancer.gov\/data\/citation.html."},{"key":"10.1016\/j.blre.2026.101435_bb0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V84.2.570.570","article-title":"Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study","volume":"84","author":"Rubnitz","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.17","article-title":"The evolution of clinical trials for infant acute lymphoblastic leukemia","volume":"4","author":"Kotecha","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101435_bb0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/hematology.2022000359","article-title":"Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy","volume":"2022","author":"Kotecha","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2026.101435_bb0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41408-023-00924-5","article-title":"Late effects in survivors of infant acute lymphoblastic leukaemia-a study of the Australian and New Zealand Children\u2019s Haematology\/Oncology Group","volume":"13","author":"Mironova","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101435_bb0040","article-title":"KMT2A-rearranged acute lymphoblastic leukaemia","volume":"4","author":"Kotecha","year":"2024","journal-title":"EJC Paediatr Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2021.11.001","article-title":"Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance","volume":"164","author":"Nijstad","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0050","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2026.101435_bb0055","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101435_bb0060","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO-25-01806","article-title":"Sustained benefit of blinatumomab in infants with KMT2A-rearranged ALL: long-term outcomes, toxicity, and pharmacokinetics","volume":"44","author":"Vieira Martins","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0065","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101435_bb0070","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2026.101435_bb0080","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/bloodadvances.2024012638","article-title":"Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL","volume":"9","author":"Annesley","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101435_bb0085","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/bjh.17333","article-title":"Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series","volume":"193","author":"Brivio","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0095","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0100","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2007-05-091934","article-title":"Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia","volume":"110","author":"Stam","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0105","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-gene\u2013rearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0115","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood-2017-01-764316","article-title":"An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts","volume":"130","author":"Schewe","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.48","article-title":"Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade","volume":"8","author":"Schewe","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2026.101435_bb0125","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia","volume":"19","author":"Carol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101435_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27765","article-title":"Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts","volume":"66","author":"Jones","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2017.294","article-title":"NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL","volume":"32","author":"Prieto","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0140","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41375-018-0353-0","article-title":"NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia","volume":"33","author":"Lopez-Millan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0145","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2023022050","article-title":"NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression","volume":"144","author":"Lopez-Millan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0150","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07100.x","article-title":"Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation","volume":"141","author":"Robinson","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0155","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood-2012-04-425033","article-title":"Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia","volume":"121","author":"Urtishak","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CE.S42568","article-title":"An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies","volume":"8","author":"Goard","year":"2013","journal-title":"Core Evid"},{"key":"10.1016\/j.blre.2026.101435_bb0165","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","article-title":"Initial testing (stage 1) of the BH3 mimetic ABT-263 by the Pediatric Preclinical Testing Program","volume":"50","author":"Lock","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0170","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101435_bb0175","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0180","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0185","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","volume":"37","author":"Cheung","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0195","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jha2.81","article-title":"Decitabine mildly attenuates MLL-rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo-sensitizer","volume":"1","author":"Schneider","year":"2020","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2026.101435_bb0200","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31630","article-title":"Venetoclax combined with chemotherapy in pediatric and adolescent\/young adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"72","author":"Place","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0210","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101435_bb0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101435_bb0220","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"Cuglievan","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0225","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101435_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116020","article-title":"Distinct responses to menin inhibition and synergy with DOT1L inhibition in KMT2A-rearranged acute lymphoblastic and myeloid leukemia","volume":"25","author":"Adriaanse","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101435_bb0235","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101435_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100148","article-title":"Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition","volume":"2","author":"Sharma","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.blre.2026.101435_bb0245","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","article-title":"Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia","volume":"128","author":"Shukla","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0250","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2022-157225","article-title":"Preclinical in vivo activity of the menin inhibitor ziftomenib (KO-539) in pediatric KMT2A-rearranged acute lymphoblastic leukemia","volume":"140","author":"Falkenstein","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0260","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options","volume":"114","author":"Stumpel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0265","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","article-title":"Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting","volume":"115","author":"Schafer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0270","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2010.282","article-title":"Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale","volume":"25","author":"Stumpel","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0275","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/leu.2011.278","article-title":"Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia","volume":"26","author":"Stumpel","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26251","article-title":"DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites","volume":"64","author":"Bergmann","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0285","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138833","article-title":"Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia","volume":"131","author":"Tejedor","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101435_bb0290","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.3324\/haematol.2024.285158","article-title":"Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL15P1","volume":"109","author":"Guest","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0295","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","article-title":"Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia","volume":"150","author":"Moreno","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0300","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.leukres.2013.07.016","article-title":"The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia","volume":"37","author":"Gruhn","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101435_bb0305","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.15436","article-title":"Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases","volume":"182","author":"Vega-Garc\u00eda","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/leu.2016.165","article-title":"Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin","volume":"31","author":"Cruickshank","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0315","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2018.192906","article-title":"Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia","volume":"104","author":"Cheung","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0320","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1200\/JCO.2006.06.4964","article-title":"Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children\u2019s Oncology Group report","volume":"24","author":"Fouladi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06916-w","article-title":"Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia","volume":"7","author":"Verbeek","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.blre.2026.101435_bb0330","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2017.216","article-title":"The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20\/RNF40\/WAC-H2B ubiquitination axis","volume":"32","author":"Garrido Castro","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0335","article-title":"The combination of curaxin CBL0137 and histone deacetylase inhibitor panobinostat delays KMT2A-rearranged leukemia progression","volume":"12","author":"Xiao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0340","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08880018.2020.1752869","article-title":"A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies","volume":"37","author":"Goldberg","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0345","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1002\/cncr.33156","article-title":"Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia","volume":"126","author":"Karol","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0350","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2021.12.078","article-title":"CN470 is a BET\/CBP\/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia","volume":"590","author":"Imayoshi","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2026.101435_bb0355","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1535-7163.MCT-17-1123","article-title":"Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4+ infant ALL","volume":"17","author":"Bardini","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2026.101435_bb0360","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/bloodadvances.2019000586","article-title":"Efficacy of combined CDK9\/BET inhibition in preclinical models of MLL-rearranged acute leukemia","volume":"4","author":"McCalmont","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101435_bb0365","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2026.101435_bb0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.celrep.2013.06.013","article-title":"Facilitates chromatin transcription complex is an \u201caccelerator\u201d of tumor transformation and potential marker and target of aggressive cancers","volume":"4","author":"Garcia","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2026.101435_bb0375","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/ijc.32582","article-title":"Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia","volume":"146","author":"Somers","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26263","article-title":"Initial testing (stage 1) of the curaxin CBL0137 by the Pediatric Preclinical Testing Program","volume":"64","author":"Lock","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0385","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.2020.38.15_suppl.3583","article-title":"Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors","volume":"38","author":"Sarantopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.2006.06170.x","article-title":"Proteasome inhibition as novel treatment strategy in leukaemia","volume":"134","author":"Vink","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0395","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccr.2014.03.008","article-title":"Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4","volume":"25","author":"Liu","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101435_bb0400","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41467-023-36370-x","article-title":"Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia","volume":"14","author":"Kamens","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101435_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.631594","article-title":"Preclinical evaluation of carfilzomib for infant KMT2A-rearranged acute lymphoblastic leukemia","volume":"11","author":"Cheung","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0410","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1038\/s41388-020-01408-7","article-title":"Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors","volume":"39","author":"Ge","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2026.101435_bb0415","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2352-3026(25)00357-6","article-title":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study","volume":"13","author":"Gruber","year":"2026","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0420","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0425","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pbc.24235","article-title":"Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program","volume":"60","author":"Carol","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0430","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/pbc.26064","article-title":"Initial testing (stage 1) of MK-8242-a novel MDM2 inhibitor-by the Pediatric Preclinical Testing Program","volume":"63","author":"Kang","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0435","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-14-2300","article-title":"Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia","volume":"21","author":"Richmond","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101435_bb0440","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101435_bb0445","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2016.07.004","article-title":"A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory\/recurrent acute myelogenous leukemia (AML)","volume":"48","author":"Ravandi","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101435_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030638","article-title":"High-throughput drug library screening in primary KMT2A-rearranged infant ALL cells favors the identification of drug candidates that activate P53 signaling","volume":"10","author":"Wander","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2026.101435_bb0455","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11523-025-01186-w","article-title":"Idasanutlin in combination with chemotherapy or venetoclax in pediatric and young adult patients with relapsed\/refractory solid tumors (iMATRIX Idasa): results of a phase I\/II, multicenter, multi-arm study","volume":"21","author":"Rubio-San-Sim\u00f3n","year":"2026","journal-title":"Target Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0460","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.leu.2403321","article-title":"Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein","volume":"18","author":"Caslini","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0465","doi-asserted-by":"crossref","first-page":"14028","DOI":"10.1073\/pnas.0506464102","article-title":"The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression","volume":"102","author":"Xia","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2026.101435_bb0470","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1038\/sj.onc.1210125","article-title":"Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation","volume":"26","author":"Gaussmann","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2026.101435_bb0475","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4161\/cc.27757","article-title":"MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL","volume":"13","author":"van der Linden","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.blre.2026.101435_bb0480","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2401129","article-title":"Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia\u2014implications for treatment of infants","volume":"12","author":"Pieters","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0485","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2026.101435_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.779859","article-title":"Systematic in vitro evaluation of a library of approved and pharmacologically active compounds for the identification of novel candidate drugs for KMT2A-rearranged leukemia","volume":"11","author":"Karsa","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0495","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-020-0895-9","article-title":"Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia","volume":"34","author":"Wander","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0500","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/pbc.20419","article-title":"Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children\u2019s Oncology Group report","volume":"46","author":"Angiolillo","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0505","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ejca.2015.06.117","article-title":"The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia","volume":"51","author":"Stumpel","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0510","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1182\/bloodadvances.2022008557","article-title":"Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16","volume":"6","author":"Gruber","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101435_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070711","article-title":"Irinotecan induces disease remission in xenograft mouse models of pediatric MLL-rearranged acute lymphoblastic leukemia","volume":"9","author":"Kerstjens","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2026.101435_bb0520","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13059-024-03260-4","article-title":"Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia","volume":"25","author":"Malyukova","year":"2024","journal-title":"Genome Biol"},{"key":"10.1016\/j.blre.2026.101435_bb0525","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","article-title":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","volume":"107","author":"Bride","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30609","article-title":"Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a Children\u2019s Oncology Group study (AINV18P1)","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0535","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2026.101435_bb0540","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood-2011-10-382861","article-title":"Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"119","author":"Kang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0545","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0550","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0555","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.blre.2026.101435_bb0560","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.12205","article-title":"MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism","volume":"160","author":"Sison","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0565","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","article-title":"Targeting CXCR4 in AML and ALL","volume":"10","author":"Cancilla","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0570","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13076","article-title":"Role of CXCR4 in the progression and therapy of acute leukaemia","volume":"54","author":"Su","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.blre.2026.101435_bb0575","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.18632\/oncotarget.2407","article-title":"Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition","volume":"5","author":"Sison","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101435_bb0580","doi-asserted-by":"crossref","first-page":"30902","DOI":"10.18632\/oncotarget.5094","article-title":"POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL","volume":"6","author":"Sison","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101435_bb0585","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26414","volume":"64","author":"Cooper","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0590","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2012.067983","article-title":"Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0595","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1038\/s41467-022-32266-4","article-title":"Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia","volume":"13","author":"Isobe","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101435_bb0600","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.18632\/oncotarget.11730","article-title":"MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations","volume":"8","author":"Kerstjens","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101435_bb0605","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3324\/haematol.2017.174060","article-title":"Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo","volume":"103","author":"Kerstjens","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0610","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.241729","article-title":"Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia","volume":"106","author":"Loftus","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0615","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1158\/2159-8290.CD-23-1376","article-title":"Efficacy of the allosteric MEK inhibitor trametinib in relapsed and refractory juvenile myelomonocytic leukemia: a report from the Children\u2019s Oncology Group","volume":"14","author":"Stieglitz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101435_bb0620","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2017.03.001","article-title":"Hoxa9 and Meis1 cooperatively induce addiction to Syk signaling by suppressing miR-146a in acute myeloid leukemia","volume":"31","author":"Mohr","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2026.101435_bb0625","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008661","article-title":"Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia","volume":"6","author":"Perova","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2026.101435_bb0630","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2012.338","article-title":"AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells","volume":"27","author":"Accordi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30398","article-title":"In vivo activity of the dual PI3K\u03b4 and PI3K\u03b3 inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts","volume":"70","author":"Randall","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0640","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-019-0692-5","article-title":"OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis","volume":"34","author":"Korotchkina","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0645","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/s41375-019-0683-6","article-title":"Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia","volume":"34","author":"Somers","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0650","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1038\/s41388-018-0666-5","article-title":"A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction","volume":"38","author":"Somers","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2026.101435_bb0655","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41416-021-01332-x","article-title":"Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin","volume":"125","author":"Karsa","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0660","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41388-022-02196-y","article-title":"Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax","volume":"41","author":"Fidyt","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2026.101435_bb0665","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-023-02414-4","article-title":"FDA-approved disulfiram as a novel treatment for aggressive leukemia","volume":"102","author":"Karsa","year":"2024","journal-title":"J Mol Med"},{"key":"10.1016\/j.blre.2026.101435_bb0670","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3324\/haematol.2024.285642","article-title":"KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges","volume":"110","author":"Stutterheim","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101435_bb0675","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/bjh.70166","article-title":"Infant acute lymphoblastic leukaemia-progress from worldwide clinical efforts","volume":"207","author":"Barrett","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0680","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood.2023023154","article-title":"How I treat infant acute lymphoblastic leukemia","volume":"145","author":"Bartram","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101435_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115809","article-title":"High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor acute lymphoblastic leukemia","volume":"217","author":"Oikonomou","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.blre.2026.101435_bb0690","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41375-025-02575-w","article-title":"DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition","volume":"39","author":"Ayyadevara","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103235","article-title":"Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia","volume":"64","author":"de Groot","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.blre.2026.101435_bb0700","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40364-025-00810-1","article-title":"HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia","volume":"13","author":"de Barrios","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.blre.2026.101435_bb0705","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/bjh.13763","article-title":"HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia","volume":"171","author":"Wu","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101435_bb0710","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2016.02.040","article-title":"Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells","volume":"375","author":"Gerges","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2026.101435_bb0715","first-page":"149","article-title":"Systematic in-vitro evaluation of the NCI\/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia","volume":"4","author":"Hoeksema","year":"2011","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.blre.2026.101435_bb0720","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3109\/10428194.2012.752079","article-title":"Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells","volume":"54","author":"Jayanthan","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101435_bb0725","doi-asserted-by":"crossref","first-page":"17284","DOI":"10.1038\/s41598-025-01657-0","article-title":"Highly specific immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia","volume":"15","author":"Jenkins","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2026.101435_bb0730","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/MPH.0000000000002697","article-title":"Establishment of a t(11;19), KMT2A rearranged B-ALL cell line for preclinical evaluation and novel therapeutics development for refractory infant leukemia","volume":"45","author":"Sharma","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101435_bb0735","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/pbc.22760","article-title":"Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement","volume":"56","author":"Jayanthan","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0740","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41388-018-0567-7","article-title":"Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia","volume":"38","author":"Urtishak","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2026.101435_bb0745","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3390\/cancers17030527","article-title":"Preclinical assessment of dactinomycin in KMT2A-rearranged infant acute lymphoblastic leukemia","volume":"17","author":"Chiu","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2026.101435_bb0750","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.18632\/oncotarget.16141","article-title":"Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101435_bb0755","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.leukres.2018.11.001","article-title":"Chemosensitivity is differentially regulated by the SDF-1\/CXCR4 and SDF-1\/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements","volume":"75","author":"Ando","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101435_bb0760","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30503","article-title":"In vivo activity of the dual SYK\/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts","volume":"70","author":"Hughes","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0765","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/sj.leu.2404277","article-title":"Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner","volume":"20","author":"Brown","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101435_bb0770","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/ijc.35362","article-title":"Polyamine depletion limits progression of acute leukaemia","volume":"156","author":"Gao","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2026.101435_bb0775","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1158\/0008-5472.CAN-16-0523","article-title":"Acute sensitivity of Ph-like acute lymphoblastic leukemia to the to the SMAC-mimetic birinapant","volume":"76","author":"Richmond","year":"2016","journal-title":"Cancer Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:04Z","timestamp":1793908024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":155,"alternative-id":["S0268960X26000743"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101435","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101435"}}